Apremilast for RAS

Learn more about:
Related Clinical Trial
Efficacy and Safety of BNP105 in the Treatment of Recurrent Aphthous Stomatitis Efficacy and Safety of BALI Association in the Treatment of Aphthous Ulcerations Hyaluronic Acid in Counteracting Aphthous Stomatitis Safety, Galenic Acceptability and Efficacy of GV-328 Lozenges in Children With Oral Aphthosis Apremilast for RAS A Trial of Pentoxifylline for the Treatment of Recurrent Aphthous Stomatitis Randomized Double Blind Controlled Trial Comparing the Safety and Efficacy of Apremilast Versus Placebo in Severe Forms of Recurrent Aphthous Stomatitis Effectiveness and Clinical Mechanism of Huanglian-Jiedu Decoction in Patients With Intense-exuberant Stomach Fire Syndrome Curcumin and Nanocurcumin in Oral Aphthous Ulcer Oral Vitamin B12 as Potential Treatment of Recurrent Aphthous Stomatitis Tokushima Night Guard for Recurrent Aphthous Stomatitis Effectiveness and Safety of Lactobacillus Rhamnosus Lcr35® in the Treatment of Recurrent Aphthous Stomatitis Therapeutic Effects of “Ibuprofen, Diphenhydramine and Aluminium MgS” on Recurrent Aphthous Stomatitis Efficacy and Safety Study of Yunnan Baiyao on Minor Recurrent Aphthous Stomatitis Topical Hyaluronic Acid and Recurrent Aphthous Stomatitis. Effect of Sodium Lauryl Sulfate on Recurrent Aphthous Stomatitis Prevention of Recurrent Aphthous Stomatitis Using Vitamins Clinical Evaluation of Fluid Extract of Chamomilla Tincture for Oral Aphthae Systemic Zinc Sulphate in Treatment of Recurrent Aphthous Ulcerations:A Doubleblind, Placebo Controled Study Influence of Different Doses of the Vitamin B12 on Recurrent Aphthous Stomatitis

Brief Title

Apremilast for RAS

Official Title

A Pilot Study Evaluating the Efficacy of Apremilast in the Treatment of Subjects With Severe Recurrent Aphthous Stomatitis (RAS)

Brief Summary

      Determination of treatment efficacy and safety of Apremilast in patients with RAS

Detailed Description

      The study will be a pilot study using apremilast 30mg orally twice daily, for treatment of
      RAS in males and females between 18 and 70 years old.

      Subjects will be recruited from the clinical practice of the Department of Dermatology or
      Division of Rheumatology at Mayo Clinic Florida. Fifteen males and females with RAS will be

      The study will consist of 3 phases: a screening phase, a 16 week treatment phase and an 8
      week posttreatment observational follow-up phase.

      The screening phase will consist of: obtaining informed consent, demographic information,
      medical history, inclusion and exclusion criteria, prior and concomitant medication use,
      adverse events; collecting vital signs and weight; performing complete physical examination
      and limited physical examination; obtaining hematology, serum chemistry, urinalysis,
      pregnancy test and providing contraception education.

      During the 16-week treatment phase, all subjects receive apremilast.

      All subjects who complete the active treatment phase are to enter the 8-week posttreatment
      observational follow-up phase.

Study Phase

Phase 4

Study Type


Primary Outcome

Duration of RAS Lesions

Secondary Outcome

 Adverse Events


Recurrent Aphthous Stomatitis


Apremilast 30mg

Study Arms / Comparison Groups

 Single Arm
Description:  Apremilast 30mg orally twice daily for 16 weeks, sixteen weeks on active study. Post treatment follow-up period of 8 weeks, in the Treatment of Subjects with Severe Recurrent Aphthous Stomatitis (RAS)


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

October 12, 2018

Completion Date

July 14, 2021

Primary Completion Date

July 14, 2021

Eligibility Criteria

        Inclusion Criteria

          1. Male and female subjects between 18 and 70 years of age

          2. Oral ulcers that occurred at least monthly in the 6 month period prior to enrollment

          3. Had at least 2 oral ulcers in the 4 weeks prior to enrollment at baseline

          4. At least 3 oral ulcers during an ulcer flare

          5. Patients must be candidates for systemic therapy for the treatment of oral ulcers,
             those that are considered unsuitable for topical therapy alone based on severity of
             disease, or whose oral ulcers cannot be adequately controlled with topical therapy.

          6. Female premenopausal subjects must use one of the approved contraceptive options while
             taking apremilast and for at least 28 days after administration of the last dose of

          7. Patients are able and willing to provide written informed consent after the nature of
             the study is fully explained.

          8. No evidence of systemic disease

        Exclusion Criteria

          1. Prior use of apremilast.

          2. Use of any investigational drug within 4 weeks prior to randomization, or 5
             pharmacokinetic/pharmacodynamic half-lives, if known (whichever is longer).

          3. Having received concomitant immune modulating therapy 12 weeks prior to enrollment,
             systemic steroids 6 weeks prior to enrollment or topical steroids within 4 weeks prior
             to enrollment.

          4. Pregnant women or breast-feeding mothers.

          5. Systemic or opportunistic fungal infection.

          6. Known active current or history of recurrent bacterial, viral, fungal, mycobacterial
             or other infections (tuberculosis and atypical mycobacterial disease, hepatitis B and
             C and herpes zoster, histoplasmosis, coccidiomycosis) or any major episode of
             infection requiring hospitalization or treatment with IV or oral antibiotics within 4
             weeks of the screening phase.

          7. History of positive test for, or any clinical suspicion of, human immunodeficiency
             virus (HIV), or congenital or acquired immunodeficiency.

          8. History of depression.

          9. Malignancy or history of malignancy, except for:

             a - treated (ie, cured) basal cell or squamous cell in situ skin carcinomas; b -
             treated (ie, cured) cervical intraepithelial neoplasia (CIN) or carcinoma in situ of
             cervix with no evidence of recurrence within the previous 5 years.

         10. Other than disease under study, any clinically significant (as determined by the
             Investigator) cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic,
             renal, hematologic, immunologic disease, or other major disease that is currently

         11. Any condition, including the presence of laboratory abnormalities, which would place
             the subject at unacceptable risk if he/she were to participate in the study.

         12. Prior history of suicide attempt at any time in the subject's life time prior to
             screening or randomization, or major psychiatric illness requiring hospitalization
             within the last 3 years.

         13. Active substance abuse or a history of substance abuse within 6 months prior to

         14. Presence of any of the following vitamin deficiencies - B1, B2, B6, B12, vitamin C,
             zinc, folate, iron.

         15. Celiac disease.

         16. Inflammatory Bowel Disease.

         17. Genital aphthous ulcers.

         18. Behçet's disease.

         19. History of positive patch test for allergic contact stomatitis.

         20. Positive anti-endomysial or anti-gliadin antibodies.

         21. A diagnosis of uveitis (current or previous).

         22. Erythema nodosum-like lesions (current or previous).

         23. An established diagnosis of a systemic disease (SLE, Reiter's, Sweet's and MAGIC




18 Years - 70 Years

Accepts Healthy Volunteers



Alison J Bruce, , 

Location Countries

United States

Location Countries

United States

Administrative Informations



Organization ID


Responsible Party

Principal Investigator

Study Sponsor

Mayo Clinic



Study Sponsor

Alison J Bruce, Principal Investigator, Mayo Clinic

Verification Date

June 2022